OncoCyte Corporation
OCX
$2.88
$0.041.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -148.36% | -197.86% | 50.38% | 42.92% | -146.45% |
| Total Depreciation and Amortization | 65.59% | 4.29% | -2.69% | 3.08% | -23.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 278.13% | 1,377.98% | -115.08% | -66.43% | 438.88% |
| Change in Net Operating Assets | -57,850.00% | 99.83% | -215.70% | 299.80% | -551.33% |
| Cash from Operations | 3.55% | 7.14% | -56.08% | 13.43% | -17.38% |
| Capital Expenditure | -145.98% | 54.45% | -695.83% | 90.91% | -1,452.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -141.38% | 54.45% | -695.83% | -123.30% | -51.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 4.65% | -160.61% | -- | -- | 0.00% |
| Issuance of Common Stock | 66,505.56% | -99.89% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 100.00% | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -472.19% | 65.24% | -- | -- | -- |
| Cash from Financing | 4,349.80% | -102.59% | -- | -- | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 189.48% | -260.22% | 195.43% | 11.42% | -21.37% |